Home > List All Publishers > BioSeeker Group AB

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.
BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker Group clients and projects are kept confidential.

List of reports from BioSeeker Group AB

Nordic Life Science Industry Guide 2008 3/18/2008 \| published by: BioSeeker Group AB ... 17 different industry segments, such as Medical Device, Diagnostics, Pharmaceuticals/Therapeutics etc. Depending on size and maturity each company is described with contact details and a short company profile. In all this CD contains close to ... \| more...	$289.00
Guide to Venture Capital in European Biopharma 9/14/2004 \| published by: BioSeeker Group AB ... the same level of seriousness and professionalism as any other serious business objective. This report is designed to speed up your VC raising campaign by distilling the information and knowledge you need to proceed efficiently. ... \| more...	$443.00
Swedish Biopharma Profiles 2002 9/25/2002 \| published by: BioSeeker Group AB ... development (R&D) or search and development (S&D) in Sweden. We also present which major disease groups are targeted and the geographical distribution of biopharma companies in Sweden. Each profile contains contact details, financial information covering ... \| more...	$471.15
R&D in Swedish Biopharma Companies 2002 9/25/2002 \| published by: BioSeeker Group AB ... in 52 identified biopharma companies in Sweden. The predominant disease groups for R&D in Swedish biopharma are: Inflammation / autoimmune, metabolic, cancer, infectious, and neurological diseases, whilst treatments for dermatitis, psoriasis, asthma and osteoporosis are ... \| more...	$492.75
Pan-European Investors in Biotechnology 2/1/2002 \| published by: BioSeeker Group AB ... contact information: phone, fax, email, website and ordinary mail. More than 320 companies have their own website for in depth information about their activity. The companies in the report are indexed alphabetically, by country and ... \| more... Search inside this report	$538.65
The Next Generation of Antifungals: Triazoles vs. Peptides 10/8/2002 \| published by: BioSeeker Group AB ... available", they continue, and it is a requirement for fungicidal, broad spectrum, non-toxic, orally deliverable drugs to have a low cost. During the 1990's, the U.S. systemic antifungal market has grown 25% per year. The ... \| more... Search inside this report	$668.25
World Guide to Bionanotechnology Industry and its Progression, 2nd ED 10/24/2005 \| published by: BioSeeker Group AB ... nanotechnology and biotechnology, hence the name bionanotechnology. "World Guide to Bionanotechnology Industry and its Progression" covers the convergence of these two major high-tech fields. With their large base of academic research supported by extraordinary growth ... \| more...	$699.00
The Handbook on Alliances & Deals in Biotech Business 5/4/2004 \| published by: BioSeeker Group AB ... within a 10 year period (1992-2001), from approximately 100 per year to close to 1000 per year today. In-licensing are becoming more and more important. Number of drugs that originated in-house has decreased from 80% ... \| more...	$718.00
Market Development in Anti-virals:What is Next? 8/24/2004 \| published by: BioSeeker Group AB ... $10bn and the prognosis for 2007 is that it will reach around $14bn. Surprisingly few companies share this sizeable global market, which can explain all the new entrants knocking on the door at this time. ... \| more...	$718.00
Future HCV Drug Discovery Technologies 11/25/2002 \| published by: BioSeeker Group AB ... both by academic groups and private companies, which has resulted in a drastic improvement of the possibilities for in vivo research. The main obstacle has clearly been difficulty of achieving viral replication in the laboratory ... \| more...	$735.75
ID Signaling Pathway in Oncology Drug Pipeline Update 2011 2/1/2011 \| published by: BioSeeker Group AB ... of proteins is comprised of IDs 1, 2, 3 and 4. There are today 20 companies plus partners developing 17 ID pathway targeting drugs in 58 developmental projects in cancer. In addition, the accumulated number ... \| more...	$749.00
ID Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... of proteins is comprised of IDs 1, 2, 3 and 4. There are today 33 companies plus partners developing 24 ID pathway targeting drugs in 109 developmental projects in cancer. In addition, there is 1 ... \| more...	$749.00
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2011 2/1/2011 \| published by: BioSeeker Group AB ... and the accumulated number of ceased drugs over the last years amount to another 9 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each ... \| more...	$749.00
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... in 123 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 19 drugs. Hedgehog Signaling Pathway In Oncology Drug ... \| more...	$749.00
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2012 2/21/2012 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 19 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one ... \| more...	$749.00
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2011 2/1/2011 \| published by: BioSeeker Group AB ... drugs in 83 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 5 drugs. Hedgehog Signaling Pathway In Oncology Drug Pipeline Update lists all drugs ... \| more...	$749.00
European Biotech Industry Guide 2006, 4th Ed. 2/13/2006 \| published by: BioSeeker Group AB ... updated but it has also been strengthened with over 200 biotech companies. This brings the total number of corporate profiles covered in this product to more than 3,300 from 28 different nations (see list of ... \| more...	$791.00
Finnish Biotech Industry Guide 2004 1/20/2004 \| published by: BioSeeker Group AB ... as Medical Device, Diagnostics, Pharmaceuticals/Therapeutics etc. Depending on size and maturity each company is described with contact details, management and board and a short company profile. Through a direct link to the company website, you ... \| more...	$808.65
Ion Channel Assays as Therapeutic Targets for Multiple Diseases 11/7/2002 \| published by: BioSeeker Group AB ... revealing the tissue specific distributions of ion channels, they will play a much more important role as therapeutic drug targets in the future. These advancements combined with cell-based assays providing biologically relevant information to genomic ... \| more... Search inside this report	$857.25
European Biotech Industry Guide 2007, 5th Ed. 2/7/2007 \| published by: BioSeeker Group AB ... it has also been strengthened with hundreds of biotech companies. This brings the total number of corporate profiles covered in this product to almost 4,000 from 28 different nations (see list of nations presented below). ... \| more...	$869.00
Fierce Competition for a Shrinking HCV Market 10/21/2002 \| published by: BioSeeker Group AB ... U.S. alone. Of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected ... \| more... Buy by the section \| Search inside this report	$911.25
Ion Channels as Therapeutic Targets for Multiple Diseases 11/7/2002 \| published by: BioSeeker Group AB ... in transcription profiling revealing the tissue specific distributions of ion channels, they will play a much more important role as therapeutic drug targets in the future. These advancements combined with cell-based assays providing biologically relevant ... \| more...	$924.75
New Targets and Drug Discovery Platforms in Antifungal R&D 11/25/2002 \| published by: BioSeeker Group AB ... of fungal drug resistant, drug-related toxicity, hazardous drug-drug interactions and non-optimal pharmacokinetics. This makes them inadequate in prophylactic treatments for immuno-compromised patient, such as HIV infected and patients with ongoing cancer or transplantation treatment. The ... \| more...	$1,005.75
Analytical Tool: Competitive Outlook on HCV 7/7/2004 \| published by: BioSeeker Group AB ... the HCV R&D and Business Development Database, which gives you access to substantial background information on the subject covered by the report, i.e. company profiles, R&D projects, and business collaborations. This Analytical Tool is especially ... \| more...	$1,125.00
Analytical Tool: Competitive Outlook on HCV 6/22/2004 \| published by: BioSeeker Group AB ... the HCV R&D and Business Development Database, which gives you access to substantial background information on the subject covered by the report, i.e. company profiles, R&D projects, and business collaborations. This Analytical Tool is especially ... \| more...	$1,125.00

< prev 1 2 3 4 5 6 7 8 9 10 next >